On Thursday, Shares of Mylan NV (NASDAQ:MYL), subtract -3.13% and closed at $36.84 in the last trading session. The last trading range of the stock ranges between $36.43 and $37.80. Attorney Advertising. Mylan N.V. (MYL) may be significantly overcharging patients for its EpiPen allergy shot. Since Mylan attained the drug in 2007, the price has raised six-fold, from $100 to $600 for two doses. Yet Mylan pays only $34.50 per pen.
The EpiPen is a small device that automatically injects a dose of the drug epinephrine into the thigh to counter life-threatening reactions to allergens such as peanuts, shellfish and bee stings. According to National Food Allergy Guidelines, a delay in administering epinephrine can be life-threatening.
Mylan claims the price increase can be explained by more than $1 billion it has invested to improve the EpiPen. In 2009 Mylan launched an upgraded version of the EpiPen; however, recent independent studies show there is little change to the design of the pen. PA Consulting Group, a UK-based technology consulting firm, found that “it’s the same core device that’s been used for some time.” The firm estimates the redesign may have only cost Mylan several million dollars. In 2015, the EpiPen brought in over $1 billion in sales for the company.
AbbVie Inc (NYSE:ABBV), dropped -0.88% and closed at $62.83 in the last trading session. The last trading range of the stock ranges between $62.56 and $63.21. The company’s Market capitalization is $102.95 Billion with the total Outstanding Shares of 1.63 Billion. AbbVie (ABBV), a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NBIX), recently declared that new data from two replicate Phase 3 studies evaluating the efficacy and safety of Elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, in premenopausal women with endometriosis, will be presented at the forthcoming 72nd American Society for Reproductive Medicine Scientific Congress & Expo (ASRM), October 15-19, in Salt Lake City. Additional data highlighting the economic and healthcare burden associated with endometriosis will also be presented.
“Endometriosis affects an estimated one in 10 women,1 and physicians and their patients are seeking alternative options to assist relieve symptoms of this disease,” said Rob Scott, M.D., Vice President, Development and Chief Medical Officer, AbbVie. “The data highlight the efficacy and safety profile of Elagolix in the treatment of pain associated with endometriosis, and underscore AbbVie’s efforts to assist address the needs of women suffering from endometriosis.”
Vonage Holdings Corp. (NYSE:VG), lost -0.61% and closed at $6.57 in the last trading session. The last trading range of the stock ranges between $6.44 and $6.59. During the 52-week trading session the minimum price at which share price traded, registered at $3.82 and reached to max level of $7.42. Vonage Holdings Corp. provides communications services connecting people through cloud-connected devices worldwide. It offers various business services, counting basic dial tone, call queue, conferencing, call groups, mobile functionality, CRM integration, and detailed analytics, in addition to Vonage Essential services. The company also provides home telephone replacement services through various service plans with basic features, such as voicemail, call waiting, call forwarding, simulring, visual voicemail, and extensions, in addition to area code selection, virtual phone number, and Web-facilitated voicemail. Its primary home telephone offering is Vonage World that offers unlimited domestic calling; calling to landline phones in about 60 countries; and calling to mobile phones in various countries. mobile services, counting Vonage Mobile, a mobile application that provides free calling and messaging between users who have the application, in addition to international calling to other phone; and Vonage-facilitated devices, which allow customers to use the Internet connection for their computer and telephones at the same time. Further, it offers high-speed broadband Internet service that allows calls over the Internet either from a telephone through a Vonage-facilitated device, or through soft phone software, or mobile client applications. The company sells its products through its sales agents, Websites, toll free numbers, and regional and national retailers for consumers and businesses in the United States, the United Kingdom, and Canada. As of December 31, 2015, it had about 2.5 million consumer subscriber lines and business seats.